Karl Sotlar Selected Research

Therapeutics

3/2022	EGFR Amplification Is a Phenomenon of IDH Wildtype and TERT Mutated High-Grade Glioma: An Integrated Analysis Using Fluorescence In Situ Hybridization and DNA Methylome Profiling.
3/2022	Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.
2/2022	Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer - Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT).
1/2022	Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group.
11/2020	Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer.
1/2020	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.
1/2018	Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression.
12/2016	Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia.
10/2016	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.
6/2016	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karl Sotlar Research Topics

Disease

34	Neoplasms (Cancer) 03/2022 - 10/2003
21	Systemic Mastocytosis 01/2022 - 01/2005
14	Mastocytosis 01/2022 - 04/2004
8	Breast Neoplasms (Breast Cancer) 03/2022 - 01/2006
5	Neoplasm Metastasis (Metastasis) 09/2022 - 04/2009
5	Eosinophilia 01/2022 - 04/2012
5	Inflammation (Inflammations) 01/2022 - 01/2008
5	Leukemia 01/2022 - 10/2005
4	Hypersensitivity (Allergy) 01/2022 - 01/2021
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 01/2014
4	Mast-Cell Leukemia (Leukemia, Mast Cell) 06/2016 - 10/2005
3	Mast Cell Activation Disorders (Mast-Cell Disease) 01/2022 - 01/2020
3	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 04/2004
3	Melanoma (Melanoma, Malignant) 04/2017 - 08/2005
3	Infections 10/2003 - 10/2002
2	Triple Negative Breast Neoplasms 09/2022 - 01/2018
2	Hereditary alpha-tryptasemia syndrome 01/2022 - 11/2021
2	Myocarditis (Carditis) 01/2022 - 08/2019
2	Disease Progression 01/2020 - 01/2007
2	Anemia 11/2019 - 01/2003
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2018 - 10/2014
2	Hypoxia (Hypoxemia) 12/2015 - 07/2015
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2014 - 01/2014
2	Prostatic Neoplasms (Prostate Cancer) 12/2010 - 07/2010
2	Ductal Carcinoma 05/2006 - 05/2006
2	Paraganglioma (Paragangliomas) 07/2005 - 04/2004
1	Oligodendroglioma 04/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Primitive Neuroectodermal Tumors (PNET) 11/2021
1	Glioma (Gliomas) 08/2021
1	Thrombocytosis (Thrombocythemia) 01/2021
1	Overweight 01/2021
1	Carcinogenesis 11/2020
1	Diabetes Mellitus 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Lung Diseases (Lung Disease) 01/2020
1	Obesity 01/2020
1	Thrombocytopenia (Thrombopenia) 11/2019
1	Noninfiltrating Intraductal Carcinoma (DCIS) 09/2018

Drug/Important Bio-Agent (IBA)

13	Tryptases (Tryptase)IBA 01/2022 - 11/2010
8	Proteins (Proteins, Gene)FDA Link 03/2022 - 05/2006
5	Codon (Codons)IBA 08/2014 - 03/2003
4	Biological ProductsIBA 01/2022 - 10/2005
4	midostaurinIBA 01/2022 - 06/2016
4	DNA (Deoxyribonucleic Acid)IBA 06/2014 - 11/2002
3	ErbB Receptors (EGF Receptor)IBA 03/2022 - 01/2007
3	MicroRNAs (MicroRNA)IBA 03/2022 - 11/2020
3	Cladribine FDA LinkGeneric 01/2022 - 10/2005
3	Pharmaceutical PreparationsIBA 01/2022 - 01/2007
3	CytokinesIBA 01/2022 - 04/2012
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 01/2005
3	VaccinesIBA 01/2021 - 10/2002
3	Hemoglobins (Hemoglobin)IBA 11/2019 - 05/2006
3	ParaffinIBA 09/2018 - 04/2004
3	Progesterone Receptors (Progesterone Receptor)IBA 01/2018 - 05/2006
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 10/2003
3	Ki-1 AntigenIBA 12/2015 - 04/2011
3	Imatinib Mesylate (Gleevec)FDA Link 07/2011 - 01/2005
2	Immunoglobulin E (IgE)IBA 01/2022 - 01/2022
2	Monoclonal AntibodiesIBA 01/2019 - 01/2008
2	Formaldehyde (Formol)FDA Link 09/2018 - 01/2006
2	Messenger RNA (mRNA)IBA 01/2018 - 04/2011
2	AntigensIBA 05/2014 - 08/2005
2	OligonucleotidesIBA 12/2012 - 05/2006
2	Keratins (Keratin)IBA 09/2012 - 01/2008
2	Radioisotopes (Radionuclides)IBA 12/2010 - 05/2006
2	MART-1 AntigenIBA 04/2009 - 08/2005
2	Estrogen ReceptorsIBA 01/2008 - 05/2006
2	AntibodiesIBA 08/2005 - 10/2003
2	Succinate Dehydrogenase (Fumarate Reductase)IBA 07/2005 - 04/2004
1	Temozolomide (Temodar)FDA LinkGeneric 04/2022
1	human MIRN3651 microRNAIBA 03/2022
1	human ERBB2 proteinIBA 02/2022
1	Hormones (Hormone)IBA 02/2022
1	Phenobarbital (Luminal)FDA Link 02/2022
1	avapritinibIBA 01/2022
1	Arthropod VenomsIBA 01/2022
1	Genetic Markers (Genetic Marker)IBA 01/2022
1	Retinaldehyde (Retinal)IBA 11/2021
1	LigandsIBA 08/2021
1	B7-H1 AntigenIBA 08/2021
1	Janus Kinase 2IBA 01/2021
1	Alkaline PhosphataseIBA 01/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	IronIBA 01/2020
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 08/2019
1	EpitopesIBA 01/2019
1	Core Binding Factors (Core-Binding Factor)IBA 01/2019
1	HematinicsIBA 10/2018

Therapy/Procedure

19	Therapeutics 03/2022 - 10/2004
4	Drug Therapy (Chemotherapy) 01/2020 - 01/2005
3	Lasers (Laser) 09/2018 - 05/2006
3	Lymph Node Excision (Lymph Node Dissection) 12/2010 - 04/2009
2	Adjuvant Chemotherapy 02/2022 - 04/2014
2	Hematopoietic Stem Cell Transplantation 01/2017 - 10/2016
1	Craniotomy 09/2022
1	Adjuvant Chemoradiotherapy 04/2022
1	Premedication 01/2021
1	Subcutaneous Injections 08/2019